

SDC/Gavi Webinar - Toward equitable access to SARS-CoV-2 vaccines for all


Daniel Thornton, Senior Adviser, Gavi

17 February 2021



The pandemic poses the greatest threat to global health security in a century

WHO Coronavirus Disease (COVID-19) Dashboard
Data last updated: 2021/2/9, 10:19am CET




2.4m+
deaths

110m+
cases


“we estimate that faster progress on ending the health crisis will raise global income cumulatively by \$9 trillion over 2020–25, with benefits for all countries, including around \$4 trillion for advanced economies.”
IMF’s Chief Economist

The COVAX pillar is the engine to deliver on the ACT-A objectives by accelerating fair and equitable access to vaccines at scale


Access to COVID-19 Tools Accelerator (ACT-A)



“COVAX” pillar



COVID-19 vaccine landscape: 49 in clinical evaluation



● COVAX MoU or Sol signed
 ● EUA¹ from SRA
 ● CEPI agreement signed
 COVAX R&D candidate
 CEPI funded candidate for R&D outside COVAX R&D portfolio
 — Discontinued

Source: RDMIC Secretariat

Candidates that have not been able to confirm the dosing of the first subject have not been included in this mapping (e.g. Providence, Kentucky, U. Tübingen). 1. Emergency use authorisation (EUA) from a stringent regulatory authority (SRA).

Progress on Agreements with Suppliers



SII deal gives AMC92 economies access to vaccines licensed from Novavax and AstraZeneca






1. [Gavi press release](#)
2. [Gavi press release](#)
3. [Gavi press release](#)
4. [Gavi press release](#)
5. [Gavi press release](#)

To date, the COVAX Facility has signed agreements with six candidates...

- Deal with **SII** to provide doses for AMC92 economies
SII / AstraZeneca collaboration announced on Aug 7, 2020¹
SII / Novavax collaboration announced on Sep 29, 2020²
- Deal with **AstraZeneca** announced on Dec 17, 2020³
- Deal with **Pfizer / BioNTech** announced on Jan. 22, 2021⁵
- MoU with **Janssen / J&J** announced on Dec 17, 2020³
- Statement of Intent with **Sanofi / GSK**, announced on October 28, 2020⁴

COVAX is actively negotiating deals with several candidates, with further announcements expected in the near-term

COVAX AMC: a reality underway

-  US\$ 2.6 billion raised, and an additional US\$ 4 billion from the US
-  At least 1.3 billion doses secured in 2021
-  Half a billion roll out scheduled in first half of 2021
-  The priority is to procure and roll out the vaccines in low- and middle-income countries
-  To reach our goal we need **at least** an additional US\$ 2 billion by Q2 2021.

The COVAX AMC needs additional funding of \$2bn by Q2 2021

- \$2.5bn + \$4bn from US pledged


Donor Governments	Contribution (US\$ million)	Donor Governments	Contribution (US\$ million)	Donor Governments and other donors	Contribution (US\$ million)
Australia	58	Netherlands	35	Other sovereign donors (including Belgium, Bhutan, Colombia, Denmark, Estonia, Greece, Iceland, Luxembourg, Monaco, Singapore)	117
Austria	2.9	New Zealand	11		
Canada	246	Norway	140		
European Commission	117	Qatar	10		
France	117	Saudi Arabia	153		
Germany	121	Spain	59		
Italy	103	Sweden	22		
Japan	200	Switzerland	22		
Korea	10	United Kingdom	735		
Kuwait	10				
				Private Sector	85

COVAX AMC global supply forecast by AMC-eligible participants - 2021

AS PER 2021-01-19

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX AMC Available Supply, Cumulative, Mn doses, 2021¹



¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).


Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.


COVAX AMC global supply forecast by region - 2021



AMC91-supported countries and number of doses, to end of 2021


[Design note: Marshall Islands no longer included (version 15 Feb 2021)]

Breakdown of AMC expenditures



Additional donor pledges needed ahead of March 2021 to exercise firm orders

AMC supply forecast over time



Preparing for delivery



Several steps are key for country readiness for Q1 2021

Nov. 2020

Dec. 2020

Jan. 2021 onwards

First allocations

First delivery

Establish National Task Force
(coordination/advisory groups)

Establish/engage with existing groups responsible
for planning; assign leader/focal point

Fill in VIRAT to facilitate planning

Develop national plan and strategy

Health care workers are critical priority
(where they are/how they will be reached)

27 Nov | Submit TA request (if applicable)

7 Dec | Submit T&C, Vx Request Form

Submit national deployment and vaccination plan (NDVP)

Submit CCE support request (if applicable)

Work with World Bank financing team to confirm eligibility; apply for financial resources

Prepare Indemnification & Liability,
regulatory systems for taking up vaccines

Keep ongoing communications with COVAX Facility
(inc. check-ins with participant/regional representatives, SCMs, AMC briefings, etc.)

Recurring/ongoing activity



WHO



Gavi/Office of COVAX Facility



UNICEF/PAHO



World Bank

COVAX

Thank you



Building the AMC: the path to equitable access



Country Engagement & Vaccine Deals

More than 150 countries engaged in COVID-19 vaccine global access facility

92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC

COVAX announces additional deals to access promising COVID-19 vaccine candidates; **plans global rollout starting Q1 2021**

COVAX announces signed deal with Pfizer for 40m doses

Publicly announced COVAX deals, to **secure additional doses in 2021**

Resource Mobilisation

Gavi launches the innovative financing mechanism **COVAX AMC** as the first building block of the COVAX Facility. **\$500m raised.**

Over **US \$2 billion** raised to support equitable access to COVID vaccines with additional **US\$ 5 billion** needed in 2021

Gavi welcomes US contribution of **\$4 billion** in supplemental funding for procurement and delivery.

The COVAX AMC needs at least an additional US \$2 billion by June 2021 to deliver equitable access to COVID-19 vaccines

Advocacy Key Moment

EC hosts Coronavirus Global Response Pledging Event

UK Hosts Global Vaccine Summit



4 June

Global Goal: Unite for Our Future

G20 Call to Action

UNGA

Paris Peace Forum

Vaccine Summit **COVAX AMC**



June 2021

The Campaign ahead: cascading moments to build up momentum

